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{Department of Mechanical Engineering, University of Maryland, College Park, MarylandABSTRACT We find evidence for a direct transition of insulin monomers into amyloid fibrils without measurable concentrations
of oligomers or protofibrils, suggesting that fibrillogenesis may occur directly from assembly of denaturing insulin monomers
rather than by successive transitions through protofibril nuclei. To support our finding, we obtain size distributions using electro-
spray differential mobility analysis (ES-DMA), which provides excellent resolution to clearly distinguish among small oligomers
and rapidly generates statistically significant size distributions. The distributions detect an absence of significant peaks between
6 nm and 17 nm as the monomer reacts into fibers—exactly the size range observed by others for small-angle-neutron-
scattering-measured intermediates and for circular supramolecular structures. They report concentrations in the nanomolar
range, whereas our limit of detection remains three-orders-of-magnitude lower (<5 pmol/L). This finding, along with the lack
of significant increases in the b-sheet content of monomers using circular dichroism, suggests monomers do not first structurally
rearrange and accumulate in a b-rich state but react and reorganize at the growing fiber’s tip. These results quantitatively inform
reaction-based theories of amyloid fiber formation and have implications for neurodegenerative, protein conformation ailments
including Alzheimer’s disease and bovine spongiform encephalopathy.INTRODUCTIONThe molecular rearrangement of soluble proteins into insol-
uble fibers is a common attribute of more than 20 diseases
including Alzheimer’s disease, Parkinson’s disease, spongi-
form encephalopathies (including mad cow disease), and
other prion diseases (1–8). The proteins at their origin take
the appellation ‘‘amyloid’’ due to the superficial resemblance
between the insoluble fibers they form and starch (Latin:
amylum) fibers. The temporal evolution of individual
proteins into fibers can be followed optically (e.g., visible
ultraviolet spectroscopy (UV-vis) at long wavelengths, bire-
fringence with staining, etc.) as depicted in Fig. 1 A. The
profile in the figure, which is characteristic of fibrillogenesis
in all these diseases, depicts a lag-time followed by a rise in
absorbance and eventually a plateau. For insulin in acetic
acid buffer with pH of 2.1 incubated at 65C, the time-lag
is ~25 h (see Fig. 1 A) (9,10). During the early portion of
the rise, insulin molecules begin to form fibers. Yet, how
exactly amyloid proteins develop into fibers remains unclear.
One school of thought holds that individual molecules
(monomers) denature in solution first and then add directly
to a growing fiber, perhaps generating synaptotoxic dimers
and trimers as reactive intermediates. Shankar et al. (11) iso-
lated these soluble intermediates (i.e., dimers and trimers) of
Ab in samples of human brains from soluble monomers and
insoluble fibers and injected theminto rats. Those that receivedSubmitted August 9, 2010, and accepted for publication October 6, 2010.
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0006-3495/10/12/3979/7 $2.00the dimers developed symptoms characteristic of Alzheimer’s
diseasewhereas the others did not. An alternate line of inquiry
suggests that individual protein molecules form into oligo-
meric structures that act as nuclei for fiber formation. Exam-
ples of these 13-nm to 23-nm-sized structures were reported
by Quist et al. (12) for several disease-related proteins. This
explanation is appealing, because it provides a mechanism
for neurodegenerative diseases. Some of these oligomeric
structures may act as ion pores when they fuse with the
neuronal cell membranes. Electrical signals transiting the
neuron then attenuate due to electrolyte leakage, disrupting
signal transduction and giving rise to cognitive disorders (13).
Although detecting soluble oligomers is essential to sort-
ing between these mechanisms, it remains difficult at low
concentrations, small size scales, and early times. Previous
instruments used to probe the monomers and oligomers
include cryo transmission electron microscopy, atomic force
microscopy (AFM), and small-angle neutron and x-ray scat-
tering (14–17). A highlight of a recent small-angle neutron
scattering study showed a distinct jump in the kinetics
when the ensemble size reached a radius of gyration of
3.95 0.2 nm (equivalent to an external diameter of 9.55
0.5 nm), providing further corroboration of a critical nucleus
composed of six monomers (14,15). Although these
techniques (including optical ones) add valuable informa-
tion, they are either: not quantitative without extensive stan-
dards and calibration; fail to provide a complete size
distribution; may present anomalous results as protein conju-
gates interact with and dry onto substrates; or demanddoi: 10.1016/j.bpj.2010.10.010
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FIGURE 1 Temporal evolution of individual proteins into fibers and
measurement method. (A) Absorption intensity at 600 nm versus incubation
time at 65C for insulin samples prepared at 2 mg/mL in 25% acetic acid,
pH 2.1. A sigmoidal curve fits the data and guides the eye. (Insets) Insulin
solution turns opaque as fibers form. (B) Diagram of ES-DMA measure-
ment system (not to scale) consisting of electrospray to produce highly
charged, aerosolized droplets; a charge neutralizer to reduce the charge
on the drying proteins to þ1, 0, or 1; a differential mobility analyzer to
separate positively charged particles based on their charge-to-size ratio;
and a condensation particle counter to individually count size-separated
particles. The panel depicts a dimer adopting several orientations on its
trajectory through the DMA. (C) Electrospray voltage versus pH of an ace-
tic acid solution with sheath gas flow rate of 1.2 L/min. The stable cone-jet
flow region, with acceptable operating region for the electrospray portion of
the ES-DMA system (green).
3980 Pease III et al.painstaking and time-consuming efforts to provide statistical
confidence. In addition, none of these techniques has
convincingly demonstrated that nuclei convert into fibers,Biophysical Journal 99(12) 3979–3985although many experimental and theoretical reaction models
have assumed this to occur.
Electrospray differential mobility analysis (ES-DMA)
provides unparalleled resolution to clearly distinguish
among small oligomers and rapidly generates statistically
significant size distributions (18–20). We have previously
used ES-DMA (see Fig. 1 B) to characterize weakly bound
antibody aggregates, distinguishing monomers, dimers,
trimer, tetramers, pentamers, and higher-order aggregates
with a lower limit of detection of 1.2 nmol/L (18). These
oligomers spanned 8–16 nm in size, approximately the size
of the oligomers observed by Quist et al. (12) on substrates.
Here we examine insulin as our model of amyloid fibrillo-
genesis. Fifty-one amino acids comprise the insulinmonomer,
the fibrillation of which has been associated with clinical
pathology (9,10). For example, insulin fibers have been found
on the arterial walls of type II diabetes patients. Additionally,
during the preparation of recombinant insulin for clinical use,
it may be subjected to low pH, high ionic strength, high shear,
or organic solvents—all conditions that may be conducive to
fibrillation. Thus, patients who receive continuous subcuta-
neous insulin infusions with micropumps and repeated insulin
shots may experience injection-localized amyloidosis. Insulin
also aggregates during the production, storage, and delivery
steps, raising concerns for the biotech companies that develop
it. In the remainder of this article, we seek to understand the
fibrillation process, identifying and kinetically tracking the
supramolecular structures formed with circular dichroism
(CD) and ES-DMA.MATERIALS AND METHODS
Buffer selection
Previous studies of insulin have shown that acidic pH, heat, and agitation
induce its fibrillation. For example, fiber formation proceeds rapidly at
2 mg/mL, pH 1.6, and 65C in 100 mmol/L of NaCl and 25 mmol/L of
HCl (9,21). Here, we incubate samples of insulin at 65C in a 25% acetic
acid in water solution at pH 2.1 and a concentration of 2 mg/mL to accom-
modate the electrospray’s conductivity window and the need for volatile
buffer ions (see Fig. 1).
The overlap of CD spectra in Fig. S1 in the Supporting Material shows
that changing the solvent does not adversely impact the three-dimensional
structure of the protein, confirming the FTIR results reported by Nielsen
et al. (22). It does, however, significantly decrease the rate of fibrillogen-
esis from 3 h for the onset of fibrillation in a NaCl/HCl solution at pH 1.6
(9,14) to ~25 h in 25% acetic acid at pH 2.1. This result agrees with the
trend noticed by Whittingham et al. (23), who found the rate of fibrillation
in acetic acid to be significantly retarded relative to that in hydrochloric
acid. Nielsen et al. (22), Ahmad et al. (24), and Hua and Weiss (25)
also point out that the fibrils formed are noticeably different, even though
insulin has similar association states in the different buffers: Insulin is
a monomer in 20% acetic acid and a mixture of monomer and dimer in
inorganic acids.Circular dichroism
Samples analyzed by CD were collected during the kinetics experiments
(2 mg/mL incubated at 65C) in 1), 100 mmol/L of NaCl and 25 mmol/L
Amyloid Fibrillogenesis 3981of HCl at pH 1.6, and 2), 25% acetic acid at pH 2.1), centrifuged at
12000 rpm for 10 min to remove insoluble fibers, and diluted in deionized
water. The dilution in deionized water instead of buffer did not affect the
spectrum of insulin (data not shown) and allowed us to record a complete
CD spectrum from 250 to 190 nm, while with the buffer 200 nm would
have been the lowest wavelength possible. CD spectra were obtained at
ambient temperature on a model No. 815 spectrophotometer (JASCO,
Easton, MD) using a 0.1 cm cell from 250 to 190 nm. For each spectrum,
a representative average of four scans was obtained using a data pitch of
0.2 nm, a bandwidth of 1.0 nm, and a scanning speed of 100 nm/min.
CD spectra of the appropriate buffers were recorded and subtracted from
the protein spectra. The molar ellipticity, q, was calculated as
q ¼ qCDMw=AA
10 d c
; (1)
where qCD is the CD signal (in mdeg), AA the number of amino acids (51 in
insulin), d the path length of the cell (0.1 cm), and c the concentration of the
protein (0.1 mg/mL).Electrospray differential mobility analysis
Size distributions were obtained using ES-DMA from samples prepared at
2.0 mg/mL incubated at 65C in 25% acetic acid (by volume) for times
ranging from 3 h to 139 h. After incubation, the samples were diluted to
50 mg/mL also in 25% acetic acid. The pressure-driven electrospray system
was used to sample aqueous solutions of soluble oligomers and short fibrils,
producing highly charged droplets which contain them. The electrospray
was operated in the stable cone-jet regime with a sheath flow rate of
1.2 L/min (1.0 L/min of air and 0.2 L/min of CO2). Fig. 1 Cmaps the condi-
tions under which a stable cone-jet can be obtained, governing our selection
of incubation conditions at pH 2.1. A single bipolar neutralizer was posi-
tioned between the electrospray and the differential mobility analyzer.
The droplets that pass into the neutralizer dry as they collide with both posi-
tively and negatively charged gas species (Fig. 1 B).
The dry proteins and protein assemblies exiting the neutralizer have
a charge distribution dominated by þ1, neutral, and 1 charge states as
described by Wiedensohler (26). Using two neutralizers results in a limit
of detection nearly two-orders-of-magnitude higher (18). Within the differ-
ential mobility analyzer, these dry proteins are exposed to electrical and
drag forces. The two forces govern the aerosolized protein’s trajectory,
such that those with the right charge-to-size ratio (the drag force scales
with size) pass via a collection slit at the end of the differential mobility
analyzer (DMA) into a single particle counter. Flow through the DMA
was set to 30 L/min of nitrogen where higher resolution was advantageous
and to 10 L/min where analysis of larger sizes proved necessary. Within
the DMA, the applied electrostatic potential ranged from 0 to 11 kV.
In the counter, termed a condensation particle counter (CPC), the size-
selected proteins act as heterogeneous nuclei, producing micron-sized
butanol droplets that are electronically enumerated as they pass in front
of a laser beam.
The entire system operates near atmospheric pressure, avoiding the
severe pressure drops that can fragment macromolecular conjugates
usually associated with electrospray ionization (i.e., like that used in
mass spectrometers operated at high vacuum). Data points were collected
at a rate of 3/min with a step interval of 0.2 nm. Conversion from mobility
diameter to length was achieved using expressions developed in detail by
Pease et al. (27) and Kim et al. (28), with a fiber diameter of 8.0 nm.
Because the DMA only counts positively charged particles, the raw
CPC count is divided by the fraction of positively charged particles
described by Wiedensohler to obtain the count for all particles regardless
of their charge state when entering the DMA (26). An overlap correction
was employed because the DMA may bin particles of the same size at two
neighboring voltages. We recently developed a correction, fno, to account
for this overlap, which is essential to determining the true concentration.At 30 L/min, fno ¼ 1 for d % 5.2 nm and fno ¼ 10.94/d29.94/d2 for
d > 5.2 nm, while at 10 L/min of sheath flow, fno ¼ 3.88/d3.58/d2 for
d > 2.4 nm and fno ¼ 1 for d % 2.4 nm (29).
The portion of the spectrum attributable to each type of peak (e.g., mono-
mer, fibers, etc.) is determined and the sum of all corrected counts corre-
sponding to the peak is determined. To determine the free insulin counts,
the counts in the dimer peak were multiplied by two, those in the trimer
peak were multiplied by three, etc., and the total counts from monomer,
dimer, and trimer were summed. Fiber counts are the sum of all overlap-
corrected counts attributable to fiber >15 nm.Atomic force microscopy
Images of insulin fibrils were obtained with an atomic force microscope
(MFP-3D; Asylum Research, Santa Barbara, CA) and standard Si cantile-
vers (AC240TS; Olympus America, Center Valley, PA). Each sample was
diluted 1:100 with deionized water and then an aliquot of 20 mL was placed
on a mica surface for adsorption for 5 min. Nonadsorbed protein was
washed away with deionized water. Three-dimensional measurements
were collected in air using the tapping mode technique of AFM. Images
were printed and then analyzed. The histogram bins were chosen to comple-
ment uncertainty in the measurement implement.Size calculations
Calculation of size was performed in Mathematica (Wolfram Research,
Champaign, IL) (18). The x, y, and z coordinates were downloaded from
RCSB Protein DataBank files (PDB) (23,30–34). To accelerate the calcula-
tions, the coordinates were digitized by rounding all coordinates to 0.5 A˚
units. Adopting the formulas given in Pease et al. (18), three orthogonal pro-
jected areas were calculated for each configuration of the insulin molecules.
This is done by projecting the centers of the atoms onto the grid with
0.25 A˚2 tiles. Because the atoms have a finite size, the van der Waals radius
of an average atom in the protein was calculated. At ~1.31 A˚, it is very
similar to the average radius for atoms in antibodies, suggesting that
this strategy is satisfactory for most proteins. A square-tiled pattern of
55 square units was then projected for each atom so that each atom
was projected over the required 6.25 A˚2 area. Then the number of nonzero
tiles corresponds to the final projected area. Because coordinate structures
for the monomer were not readily available, the RCSB PDB structure for
the dimer was used and the two largest projected areas were divided by
two to approximate the monomer.RESULTS
Structural identification in ES-DMA
Here we examine in detail the conversion of insulin into
fibers, collecting size distributions at various times. Fig. 2
A displays distributions with peaks at 2.8 nm, 3.6 nm, and
4.2 nm. To identify each of these structures, we follow Pease
et al. (18,20), who calculated the size of antibody aggregates
using structures from the RCSB Protein DataBank (23,30–
34). In their method, they use the PDB’s atomic coordinates
to calculate three orthogonal projected areas. Examples of
the three projections and their corresponding areas, Ai, are
captured in Fig. 3 for the insulin monomer and hexamer.
As the insulin adopts a new orientation with every Brownian
collision (see Fig. 1 B), the projected areas may be averaged
to determine the mobility diameter,Biophysical Journal 99(12) 3979–3985
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FIGURE 2 The conversion of native insulin into
amyloid fibrils. (A) Mobility size distribution (i.e.,
number of particles versus their spherically equiva-
lent diameter) for 2 mg/mL of insulin in 25% acetic
acid (pH2.1) heated to 65C for the time specified in
the legend and then diluted by 40 (0.05mg/mL) in
25% acetic acid for analysis. DMA operated at
30 L/min of sheath flow. (B) Free insulin counts,
CI, from ES-DMA (circle) and concentration of
free insulin via UV-vis at 280 nm (square) versus
incubation time, t. An exponential curve, CI ¼
6.3  104 (particles/cc) exp(9.7  103 t/h), fits
the data. (C) Length distribution of the same
acquired at 10 L/min assuming the insulin fiber to
be a rigid rod with a diameter of 8.0 nm as indicated
in the AFM. (D) Count of insulin fibers from
ES-DMA (circle) and absorbance/scattering at
600 nm (square) versus incubation time. (E) Histo-
gramof lengths of insulin fibers captured byAFMin
panel F binned in 50-nm increments. (F) Atomic
force microscopy image of insulin fibrils deposited
after incubation for 164 h.
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
p1=2
X
i
A
1=2
i =6
1
; (2)
so termed because it is compared with the diameter found
experimentally by determining the gas-phase electric
mobility of the protein through the DMA. Although dm is
a spherically equivalent diameter, Eq. 2 accounts for the
inherent structure of the insulin molecule through the pro-
jected areas. Via this equation, we predict the monomer to
have a mobility diameter of 2.75 nm (30,31), the dimer to
be 3.45 nm (23,32), and the trimer to range between
3.9 nm and 4.2 nm, depending on the spatial configuration
of the individual insulin molecules comprising it, as summa-
rized in Table 1. The agreement between the measured and
predicted sizes allows us to identify the peaks as labeled in
Fig. 2 A.
The PDB structures for the monomer and hexamer are
derived from NMR and each contain 10 sets of atomic coor-
dinates representing configurations of similar likelihood.
We can use these to estimate the impact of conformational
variability on the prediction of mobility size. We find the
predicted sizes for the monomer range from 2.72 nm to
2.81 nm and the hexamer to range from 5.14 nm to
5.28 nm. This result indicates that variability in the molec-
ular configuration constitutes less than half of the width ofBiophysical Journal 99(12) 3979–3985the peak (0.6 nm at its base) in Fig. 2 A, with the remaining
uncertainty being contributed by the instrument.
Monomer concentration
Not all multimers in an ES-DMA size distribution neces-
sarily exist in the solution before electrospraying. Pease
et al. (18) assert that multiple independent proteins may
collect in a single electrospray droplet and dry into an
apparent multimer, even though it did not exist in the orig-
inal solution. They show the mass concentration cutoff,
Mcutoff, above which apparent dimers must form, to be
a function of the protein molecular weight, Mw, and droplet
diameter, ddrop, as
Mcutoff ¼ 6Mw
pd3dropNA
; (3)
where NA is Avogadro’s number. We have measured the
droplet size to be 154 nm using a sucrose solution (see
Fig. S2 A), and the molecular weight of insulin is
5.81 kDa (23,32). The cutoff concentration for insulin
then becomes 5.0 mg/mL. As the cutoff lies a full order of
magnitude below our concentration (50 mg/mL), multiple
independent proteins may accumulate in a droplet. Apparent
multimers may still form below Mcutoff but must form above
FIGURE 3 Calculating the size of insulin aggregates using structures
from the RCSB Protein DataBank. (A) Ribbon diagrams for three orthog-
onal projections of the insulin monomer from the PDB entry 2HIU
(30,31). (B) Projections used to calculate the projected areas of the insulin
dimer with 0.05 nm by 0.05 nm pixels. The calculated areas (from left to
right) are 5.25 nm2, 6.79 nm2, and 5.62 nm2. (C) Ribbon diagrams for three
orthogonal projections of the insulin hexamer from the PDB entry 1AI0
(33,34). (D) Projections used to calculate the projected areas of the insulin
hexamer with 0.05 nm by 0.05 nm pixels. The calculated areas (from left to
right) are 22.72 nm2, 21.32 nm2, and 20.83 nm2.
Amyloid Fibrillogenesis 3983it. Consequently, the dimers and trimers in Fig. 2 A must
represent, at least partially, apparent dimers and trimers.
Decreasing the insulin concentration by dilution decreases
the prominence of these apparent species as seen in
Fig. S2 B.
Apparent dimers cannot be avoided in the current setup
because they remained until the lower limit of detection in
concentration which we estimate to be 5 pmol/L as indicated
in Fig. S3. We note, however, that the ES/neutralizer system
does not preferentially ionize monomeric species. Indeed, it
preferentially ionizes larger species as indicated by Wieden-
sohler (26), suggesting that oligomers, if present in appre-
ciable concentrations, would be easier to detect than
monomers. (We have accounted for this preferential
charging of larger species in figures herein by dividing theTABLE 1 Identification of key ES-DMA peaks for insulin
oligomers
Identification
Predicted
size (nm)
Measured
size (nm)
Monomer(30, 31) 2.755 0.08 2.8 5 0.3
Dimer(23, 32) 3.45 3.6 5 0.6
Trimer (triangular close packed) 3.9–4.2 4.2 5 0.7
Hexamer(33, 34) 5.205 0.14 Not observed
Hexamer of hexamers arranged annularly 9.9 Not observedmeasured number density by the size-dependent probability
of charging so that distributions more accurately reflect
solution conditions.)
It follows that a strong majority of the insulin in the
sample solution not incorporated into a fiber is present in
the monomeric state. We can, therefore, elucidate how the
concentration of free insulin decreases with incubation
time by summing the counts (not integrating) under each
peak in Fig. 2 A, multiplying the dimer count by two and
the trimer counts by three. Fig. 2 B shows the total monomer
count in solution decreases exponentially in time. An expo-
nential decay is characteristic of a first-order rate equation
as expected from fibrillation process (9). The distributions
in Fig. 2 A are remarkable because they lie at the lower
size limit of the instrument (between 1.70 nm and
2.82 nm) (35). Below 5 nm, the CPC does not operate at
full efficiency as smaller proteins fail to heterogeneously
nucleate droplets within the timescales imposed by the
instrument (35,36). This inefficiency prevents final closure
of the mass balance. Nevertheless, kinetic trends for the
monomer and fiber concentrations may be trusted (see
Fig. 2, B and D).Fiber concentration
As the free monomer concentration declines, the fiber count
increases. Fig. 2 C, which plots the aerosol phase number
density or count versus the length, shows that the counts
attributed to fibers increase with incubation time. In convert-
ing from mobility diameter (see Fig. S4 for the mobility size
distributions) to length, we followed the model of Kim et al.
(28) and Pease et al. (29), who calculate length distributions
for multi- and single wall carbon nanotubes using differen-
tial mobility analysis. They assume the nanotubes to be rigid
rods. Fig. 2 F shows that, although the insulin fibers may not
be perfectly rigid, the shorter ones do appear to be straight.
The model requires the input of a diameter which we take to
be 8.0 nm (37,38). The data in Fig. 2 C then show that the
distribution of long fibers begins to grow between 25 and
37 h and plateaus after 100 h, maintaining an approximately
constant width through the duration of fibrillogenesis.
The total counts under the peaks in the length distribution
may also be summed and compared to the UV-vis absor-
bance detected at 600 nm. Fig. 2 D shows that the rise in
absorbance mirrors the rise in fiber count with incubation
time. This agreement is important because it validates the
use of UV-vis at 600 nm as a tool to measure the total fiber
counts. The UV-vis is valuable because it is rapid and ubiq-
uitously available, though ES-DMA is faster and more
informative than competing techniques that provide size
distributions including AFM (18).
ES-DMA shows that the length distribution spans sizes
from 20 nm long to >400 nm, while the preponderance of
the distribution lies between 50 nm and 200 nm in length.
This may seem surprising in light of the AFM image inBiophysical Journal 99(12) 3979–3985
3984 Pease III et al.Fig. 2 F, where fibers several microns in length are readily
apparent. Careful analysis of the figure, however, indicates
the smaller features to be much more numerous, as depicted
in the histograms of Fig. 2 E. This DMA setup is limited to
sizes below ~600 nm (to prevent dielectric breakdown), so
the very largest but sparse features in Fig. 2 F do not appear
in the ES-DMA distributions.
We also examined the incubated sampleswithCD. TheCD
spectra represent the configuration of monomers and any
soluble oligomers. Before analysis the solution was filtered
to remove the larger, less soluble fibers. Fig. S1 B shows
that the curvature of the spectrum does not change in the
range from210nm to 225 nmduring the course of fibrillation,
as might be expected if a-helices in a significant portion of
the insulin monomers rearranged into b-sheets. Thus, insulin
monomers do not rearrange and accumulate in solution.
Previouswork by Sethuraman et al. (39,40), with the globular
protein, hen egg lysozyme, indicated that inducing misfold-
ing by exposure to a hydrophobic surface (Teflon; DuPont,
Wilmington, DE) results in two-phase unfolding kinetics;
one phase was very fast (<1 min) with a-helix to random
turns’ secondary structure, while the other phase was much
slower (~1200 min) with a-helix to b-sheet transition.DISCUSSION
Perhaps the most remarkable aspect of this kinetic data is
the lack of oligomeric species in the size distributions of
Fig. 2 A between 5 nm and 16 nm. This is particularly
surprising because several models of amyloid fibrillation
rely on the presence of oligomers, critical nuclei, or protofi-
brils. For example, Lee et al. (9) developed a kinetic model
of fiber formation, postulating monomers react to form
dimers, timers, etc., until a critical nucleus composed of
approximately six monomers is achieved. Subsequent fiber
growth continues with monomer addition. However,
a cluster size of six monomers would appear in ES-DMA
at 5.20 nm 5 0.14 nm (three standard deviations, see also
Eq. 2 and Fig. 3), whereas the largest significant peak is
the apparent insulin trimer with size of 4.2 nm.
Our data also do not support the hypothesis that an
annular structure, similar to an ion pore, plays a significant
role in the in vitro kinetics. The ion pore-like annular struc-
tures reported by Quist et al. (12) range in size from 13 nm
to 23 nm, and we estimate a hexamer of hexamers, similar to
the annular structures they report, to be ~9.9 nm in mobility
diameter. In contrast, Fig. 2 A shows a complete lack of
significant peaks between 9 and 20 nm. This may arise
either because the path to fibrillation occurs directly from
attachment of denaturing insulin monomers to fibrils rather
than through successive transitions through protofibril
nuclei or because the concentration of these nuclei remains
below the lower limit of detection of this instrument.
However, Quist et al. (12) reports that the nuclei concentra-
tion in physiological conditions exceed the low nanomolar,Biophysical Journal 99(12) 3979–3985while our limit of detection is ~5.0 pmol/L (see Fig. S3),
indicating that the latter possibility is unlikely. Indeed, our
continuing experiments find very few ion porelike structures
with AFM or cryo-transmission electron microscopy.
Our data alsoprovide insight into possible fibrillationmech-
anisms. The exponential decay of the free insulin (Fig. 2 B),
sigmoidal rise in the fiber concentration (Fig. 1 D), and rela-
tively constant width of the length distribution (Fig. 2 C) are
characteristic of chain or additional polymerization reactions.
It is also significant that the CDdata in Fig. S1B do not appear
to exhibit secondary structural changes in solution during
fibrillation. Indeed, despite the formation of significant quan-
tities of fiber, the b-sheet content does not increase. This
suggests that, despite heat and acidic conditions, the insulin
does not unravel in the bulk solution. We, therefore, suspect
that free insulin adds directly to the tip of growing fibers
without assuming intermediate forms.
Although we can clearly distinguish among the associa-
tion states of the insulin molecules, we cannot with this
technique distinguish between apparent and bona fide
dimers based solely on size. However, the ability to generate
high purity oligomers of amyloid proteins (i.e., dimers, and
trimers) with this technique may be advantageous for use in
animal or in vitro studies (11). For example, this technique
offers the capability to generate dimers without chemical
cross linkers or changes in the oxidation state, which may
be used to confirm the results of Shankar et al. (11), who
found SEC-purified dimers to be sharply synaptotoxic
upon injection into rats.CONCLUSIONS
The results presented here suggest that oligomers attach
directly to the ends of amyloid fibrils possibly without
passing through a series of intermediate to large oligomer
intermediates. They would need to unfold either in solution
or on addition to the ends of the insulin fibers where
a template structural transition to b-sheet secondary struc-
ture occurs. Measurements using ES-DMA and CD are
used to follow both size and secondary structural changes
with time along the amyloid reaction coordinate.SUPPORTING MATERIAL
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